DURBECEM Trademark

Trademark Overview

On Monday, May 18, 2020, a trademark application was filed for DURBECEM with the United States Patent and Trademark Office. The USPTO has given the DURBECEM trademark a serial number of 88921864. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Tuesday, August 20, 2024. This trademark is owned by Celgene Corporation. The DURBECEM trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
durbecem

General Information

Serial Number88921864
Word MarkDURBECEM
Filing DateMonday, May 18, 2020
Status734 - FIFTH EXTENSION - GRANTED
Status DateTuesday, August 20, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 2, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, June 4, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events

Event DateEvent Description
Thursday, May 21, 2020NEW APPLICATION ENTERED
Tuesday, August 18, 2020NON-FINAL ACTION WRITTEN
Thursday, June 4, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, August 15, 2020ASSIGNED TO EXAMINER
Tuesday, August 18, 2020NON-FINAL ACTION E-MAILED
Tuesday, August 18, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, January 11, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, January 11, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 12, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 27, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 2, 2021PUBLISHED FOR OPPOSITION
Wednesday, February 10, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 2, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sunday, March 28, 2021EXTENSION OF TIME TO OPPOSE RECEIVED
Friday, June 25, 2021OPPOSITION INSTITUTED NO. 999999
Thursday, January 6, 2022OPPOSITION TERMINATED NO. 999999
Thursday, January 6, 2022OPPOSITION DISMISSED NO. 999999
Thursday, January 6, 2022TTAB RELEASE CASE TO TRADEMARKS
Tuesday, March 1, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, March 4, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, March 4, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, March 4, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, August 23, 2022SOU EXTENSION 1 GRANTED
Tuesday, August 23, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, August 23, 2022SOU EXTENSION 1 FILED
Thursday, August 25, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 27, 2023SOU TEAS EXTENSION RECEIVED
Monday, February 27, 2023SOU EXTENSION 2 FILED
Monday, February 27, 2023SOU EXTENSION 2 GRANTED
Tuesday, August 29, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, March 1, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 29, 2023SOU EXTENSION 3 FILED
Tuesday, August 29, 2023SOU EXTENSION 3 GRANTED
Thursday, August 31, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 7, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, August 20, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, August 20, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 20, 2024SOU EXTENSION 5 FILED
Tuesday, August 20, 2024SOU EXTENSION 5 GRANTED
Wednesday, February 7, 2024SOU EXTENSION 4 FILED
Wednesday, February 7, 2024SOU EXTENSION 4 GRANTED
Friday, February 9, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

durbecem diseases pharmaceutical human preparations anti system disease cancer disorders namely